MAY 21, 2019 10:17 PM PDT

A New Class Of Depression Medication

WRITTEN BY: Abbie Arce

The National Institutes of Health (NIH) estimate that over 17 million adults in the US have had at least one major depressive episode. At any given time, another 24.4 million adults suffer from Post-Traumatic Stress Disorder (PTSD). 

All of the drug therapies available for depression today focus on suppressing the symptoms of the disorder. In the US, even with the highest percentage of the population on antidepressants than anywhere else in the world, the effectiveness of these medications is often scrutinized.

What if instead of suppressing the symptoms, we could develop a medication to help people deal with the stressful situations that cause depression and PTSD before they develop. 

In 2014, neuroscientist Rebecca Brachman and her team may have stumbled upon a drug that does just that. This newly discovered class of drugs works by increasing a person's stress resilience. The idea is that these drugs would boost a person's ability to handle extreme stressors much in the way that a vitamin might raise a person's immune response. 

In the above video, Brachman goes into detail about her incredible discovery and what it might mean for the future of treating PTSD and depression. 


Sources: TEDNational Institute of Mental Health

About the Author
  • Abbie is an AFAA certified personal trainer and fitness instructor with an interest in all things health-science. She has recently graduated with her BS in Applied Sport and Exercise Science from Barry University in Miami. Next, she intends to earn an MPH with a focus in Epidemiology.
You May Also Like
JUN 18, 2019
Microbiology
JUN 18, 2019
Using Engineered Bacteria to Rapidly Evaluate Therapeutics
Scientists are using genetic tools to engineer bacteria in many ways. These new microbes are able to mimic or sense disease states......
JUN 18, 2019
Genetics & Genomics
JUN 18, 2019
Drug Discovery
JUN 18, 2019
New Oral Drug for Multiple Sclerosis Treatment
The U.S. Food and Drug Administration has approved a new oral drug for the treatment of multiple sclerosis (MS)--a chronic, inflammatory, autoimmune diseas...
JUN 18, 2019
Cell & Molecular Biology
JUN 18, 2019
Antidote to Deadly Box Jellyfish Venom Developed Using CRISPR
The Australian box jellyfish can be deadly. They are the most venomous marine creature, and one can kill up to 60 people....
JUN 18, 2019
Drug Discovery
JUN 18, 2019
First PI3K Inhibitor for Breast Cancer
The U.S. Food and Drug Administration has approved Piqray (alpelisib) tablets, to be used in conjunction with FDA-approved endocrine therapy fulvestrant fo...
JUN 18, 2019
Genetics & Genomics
JUN 18, 2019
Clinical Trials Aim to Improve Therapeutics with Genomic Data
Scientists now have access to vast amounts of human genetic data. Now the NIH wants to put that data to use....
Loading Comments...